Document:

RSU Notification (RSU France 2014 08)

Exhibit 10.52
 
SERVICE- VESTING

Restricted Stock Unit Award Notification

To:            [FNAME] [LNAME] 
[EMAIL] 
Employee ID: [ID #] 
From:            KLA-Tencor Executive Team
Subject:            Restricted Stock Unit Grant
                            

Congratulations!  We are pleased to inform you that the Board of Directors or its Compensation Committee has granted to you an award of Restricted Stock Units under the KLA-Tencor Corporation 2004 Equity Incentive Plan (the “EIP4 Equity Plan”) and the Rules of the KLA-Tencor Corporation 2004 Equity Incentive Plan for the Grant of Restricted Stock Units to Participants in France (the “French Plan”).  Subject to the provisions of the EIP4 Equity Plan, the French Plan and the Restricted Stock Unit Agreement for French Participants (with Dividend Equivalents) (the “French RSU Agreement”), the principal features of this award are as follows:

Date of Grant:        [DATE]

Award Number:        [AWARD #] 

Number of 
Restricted Stock Units
Awarded:        [SHARES] 
Each Restricted Stock Unit represents the right to receive one share of KLA-Tencor Corporation common stock upon the satisfaction of the applicable vesting requirements set forth below. 

		
	Vesting Schedule:
	You shall vest in the Restricted Stock Units bi-annually, with 50% of the total value of the Restricted Stock Unit vesting on the 2nd annual anniversary of the Date of Grant set forth above and the remaining 50% on the 4th annual anniversary of the Date of Grant set forth above.  Each vesting event is contingent upon your continued status as a current KLA-Tencor employee as of the applicable vesting date.

Vesting in your Restricted Stock Units will cease immediately upon your termination of Service Provider status for any reason (other than termination of your Service Provider status by reason of your death), including pursuant to a reduction-in-force.

The issuance of shares of KLA-Tencor Corporation common stock upon the vesting of Restricted Stock Units is subject to compliance with all of the applicable requirements of all laws or regulations with respect to such units. Neither the grant of this award nor the vesting schedule alter the terms of your employment, which remain at-will and subject to termination by KLA-Tencor or you at any time, with or without cause or notice.

PLEASE BE SURE TO READ THE FRENCH RSU AGREEMENT, WHICH CONTAINS SPECIFIC TERMS AND CONDITIONS APPLICABLE TO THIS AWARD.  By accepting this award, you agree and understand that this award is subject to all of the terms and conditions contained in (1) this Restricted Stock Unit Award Notification, (2) the EIP4 Equity Plan document, (3) the French Plan document, and (4) the French RSU Agreement.  For copies of these plan documents, please see KLA-Tencor’s Long Term Incentives website, which can be accessed through the KLA-Tencor Intranet site: http://hronline.kla-tencor.com/incent-and-reward/long-term-incentives.

Please consult your individual tax advisors regarding any tax or other consequences related to your KLA-Tencor Restricted Stock Units.

THIS MEMO IS YOUR OFFICIAL NOTIFICATION OF THIS AWARD.  NO ADDITIONAL DOCUMENTATION WILL BE SENT TO YOU CONCERNING THIS AWARD.Exhibit 10.14

 

Execution Copy

 

CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 6 TO WORK STATEMENT NB-1

 

RADIUS HEALTH, INC., a Delaware corporation (“Radius”) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (“NB”) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S entered into the certain Clinical Trial Services Agreement (“Agreement”) and that certain Work Statement NB-1 under the Agreement as of March 29, 2011 (“Effective Date”), and entered into an Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5 to Work Statement NB-1 as of December 9, 2011, June 18, 2012, November 6, 2013, March 28, 2014 and May 19, 2014 respectively, (as amended, “Work Statement NB-1”).

 

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 6 to Work Statement NB-1 (“Amendment No. 6”) effective as of July 22, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 6 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

 

NOW THEREFORE, in consideration of the mutual covenants and promises contained in this Amendment No. 6, the parties agree as follows:

 

1. Reconciliation of costs related to clinical sites, renal CT and QCT scans and Adjustment to Payment Schedule

 

(a) At Radius’ request, NB has previously initiated 4 additional non-CCBR sites in Brazil (2), United States (1) and Hong Kong (1) and discontinued 3 non-CCBR sites in Argentina (1), Brazil (1) and the US (1) in the clinical study that is the subject of Work Statement NB-1. In addition, Radius has previously requested NB to increase the number of renal CT scans to be obtained and analyzed and to obtain new QCT scans (collectively, “A6 Services”). Radius wishes to now provide for a reconciliation of payments to NB for these A6 Services under Work Statement NB-1.

 

(b)  The NB representations and warranties set forth in Sections 8.2, 8.3, 8.5 and 8.6(ii) of the Agreement shall apply to the personnel, including the Clinical Investigators, who perform the clinical study under the A6 Services. NB shall be responsible for securing the applicable representations and warranties from these clinical study sites and personnel, including Clinical Investigators.

 

(c)  The Study Assumptions table on the first page of Attachment A to Work Statement NB-1 (Attachment 2 to the Agreement) is amended to reduce the total Number of Sites from 42 to 28 reflecting this Amendment No. 6 as well as the final number of sites, including deletion of sites in India that were not initiated by Radius. As amended, the Study Assumptions table will read as follows:

 

	
Protocol Number
    	
 
    	
BA058-05-003
    
	
Number   of Sites:
    	
 
    	
28
    
	
Denmark
    	
 
    	
3
    
	
Estonia
    	
 
    	
2
    
	
Lithuania
    	
 
    	
1
    
	
Romania
    	
 
    	
1
    
	
Poland
    	
 
    	
6
    
	
Czech Republic
    	
 
    	
3
    
	
Brazil
    	
 
    	
5
    
	
Argentina
    	
 
    	
1
    
	
Hong Kong
    	
 
    	
1
    
	
USA
    	
 
    	
5
    

 

1

 

(d) The paragraph at the bottom Attachment B to Work Statement NB-1 (Budgets, Fees, Pass-through Costs, and Payment Schedule*) is hereby amended to read in full as follows:

 

“The pricing specified in this Budget is calculated based upon 2,040 subjects randomized and completed at sites managed by NB, excluding sites in India and the United State of America, and is not subject to any adjustment for the number of patients to be Pre-screened/Advertisement, the screen failure rate after the Patient Informed Consent has been signed, or the drop-out rate. However, this Budget as well as the Bonus Equity Payment Amount under the Amended and Restated Stock Issuance Agreement dated May 16, 2011 shall each be reduced by an amount of €11,941 per subject for any subjects enrolled in India or the United States. Such reduction to be applied in pro rata installments at the time of payment of the Second Monthly Amount and the Third Monthly Amount. Otherwise, all pricing will be adjusted on a pro rata fashion to reflect the actual study activities completed by the study subjects.

 

For bone biopsies, this pro rata adjustment for biopsies less than or greater than 200 shall be €4,153 for each bone biopsy at sites managed by NB and €2,008 for sites in India and the United State of America.

 

For obtaining of CT-scans, this pro rata adjustment for CT-scans less than or greater than 300 shall be €610 for each CT-scan at sites managed by NB.

 

For CT-scans image analysis, this pro rata adjustment for CT-scans less than or greater than 300 shall be €180 for each CT-scan for all sites. In addition, there will be a charge of €4,134 for the first 100 Data Clarification Forms (DCF) and €41 for each additional DCF greater than 100. In addition, there will be a 10 per cent management charge to NB related to obtaining and the analysis of CT-scans greater than 300.

 

For obtaining QCT-scans, the cost of €176,681 for 534 QCT-scans will be sent as pass-through from Synarc, Inc. through NB and shall be adjusted on a pro-rata basis for less than 534 QCT-scans. A separate amendment agreement will be negotiated for QCT-scan image analysis between Radius and Synarc, Inc. which is not included in the Amendment No. 6.

 

The following table related to the A6 Services is inserted immediately below the above paragraph in Attachment B to Work Statement NB-1:

 

New sites:
 Brazil (125, 126) 
 HK (182), 
 US (216)
 Not active sites: 
 US (215)
 Argentina (202)
 Brazil (122)
 Extra CT scan activity

 

	
Sponsor:
    	
 
    	
RADIUS
    
	
Protocol   ID; 3 new sites
    	
 
    	
BA058-05-003
    
	
Development   Phase:
    	
 
    	
III
    
	
Disease:
    	
 
    	
Osteoporosis
    
	
Site   126: Brazil; Dr. Albergaria
    	
 
    	
49
    
	
Site   125: Brazil; Dr. Borges
    	
 
    	
12
    
	
Site 182: Hong Kong; Dr. Liu Po Lung, Paul
    	
 
    	
0
    
	
Site   216 (US)
    	
 
    	
21
    

 

2

 

	
Number   of sites in
    	
 
    	
3
    
	
Expected   Date of FPFV:
    	
 
    	
Q3-2012
    
	
Preparation   time
    	
 
    	
3
    
	
Expected   Length of Recruitment (months):
    	
 
    	
2
    
	
Treatment   Duration (months):
    	
 
    	
19
    
	
Close   Out (months)
    	
 
    	
2
    
	
Total   Study duration (Nordic involvement)
    	
 
    	
26
    
	
Number   of Visits per patient
    	
 
    	
10
    
	
Number   of patient visits
    	
 
    	
820
    

 

	
 
    	
 
    	
Responsibility
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CRO - Task Description
    	
 
    	
Radius
    	
 
    	
Nordic
    	
 
    	
Total
    	
 
    	
Remarks
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Project Coordination
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Project Management
    	
 
    	
 
    	
 
    	
X
    	
 
    	
26,000
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Prepare Study Materials
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Informed Consent local version 
    	
 
    	
 
    	
 
    	
X
    	
 
    	
0
    	
 
    	
 
    	
 
    
	
Circulate source data and other documents
    	
 
    	
 
    	
 
    	
X
    	
 
    	
3,000
    	
 
    	
Site   125, 126, 216
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Site Identification &   Initiation Visits 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Pre-Study feasibility
    	
 
    	
 
    	
 
    	
X
    	
 
    	
1,500
    	
 
    	
Site   182, 125, 126
    	
 
    
	
Site Identification
    	
 
    	
 
    	
 
    	
X
    	
 
    	
1,500
    	
 
    	
Site   182, 125, 126
    	
 
    
	
Site Selection Visits
    	
 
    	
 
    	
 
    	
X
    	
 
    	
9,000
    	
 
    	
Site   182, 125, 126
    	
 
    
	
Site Initiation Visits
    	
 
    	
 
    	
 
    	
X
    	
 
    	
9,000
    	
 
    	
Site   125, 126, 216
    	
 
    
	
Prepare site contracts
    	
 
    	
 
    	
 
    	
X
    	
 
    	
3,000
    	
 
    	
Site   182, 125, 126
    	
 
    
	
Administration of Site payment (including   calcium/D suppl)
    	
 
    	
 
    	
 
    	
X
    	
 
    	
2,000
    	
 
    	
Site   125, 126
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Study Start-up Activities
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Set-up Investigators Study File
    	
 
    	
 
    	
 
    	
X
    	
 
    	
600
    	
 
    	
Site   125, 126, 216
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Regulatory
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Submission to EC and RA; Brazil - 2 sites
    	
 
    	
 
    	
 
    	
X
    	
 
    	
38,625
    	
 
    	
Site   125, 126
    	
 
    
	
Submission to EC and RA; Hong Kong
    	
 
    	
 
    	
 
    	
X
    	
 
    	
5,000
    	
 
    	
Site   182
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Study Drug
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Coordinate Drug Shipment to sites
    	
 
    	
X
    	
 
    	
X
    	
 
    	
2,600
    	
 
    	
 
    	
 
    

 

3

 

	
Discount 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
-1,300
    	
 
    	
For   site 202 and 215 not active
    	
 
    
	
IVR training
    	
 
    	
X
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Pharmacovigilance
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Extra PV management time
    	
 
    	
 
    	
 
    	
X
    	
 
    	
7,800
    	
 
    	
 
    	
 
    
	
Discount
    	
 
    	
 
    	
 
    	
 
    	
 
    	
-2,600
    	
 
    	
For   site 202 and 215 not active
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Data Management / EDC
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Add sites to EDC System
    	
 
    	
 
    	
 
    	
X
    	
 
    	
30,000
    	
 
    	
Site   125, 126, 216
    	
 
    
	
Site Installation & Training for EDC
    	
 
    	
 
    	
 
    	
X
    	
 
    	
3,000
    	
 
    	
Site   125, 126, 216
    	
 
    
	
Data Management
    	
 
    	
 
    	
 
    	
X
    	
 
    	
52,000
    	
 
    	
 
    	
 
    
	
Discount
    	
 
    	
 
    	
 
    	
 
    	
 
    	
-26,000
    	
 
    	
For   site 202 and 215 not active
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Monitoring and site   Administration
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Extra fee to external CRO (Quintiles)
    	
 
    	
 
    	
 
    	
X
    	
 
    	
131,331
    	
 
    	
Site   125, 126 discounted for all site 202 activity
    	
 
    
	
US site 216
    	
 
    	
 
    	
 
    	
X
    	
 
    	
50,000
    	
 
    	
 
    	
 
    
	
Discount
    	
 
    	
 
    	
 
    	
 
    	
 
    	
-45,000
    	
 
    	
For   site 215 not active
    	
 
    
	
Site Contact & Administration
    	
 
    	
 
    	
 
    	
X
    	
 
    	
54,600
    	
 
    	
Site   125, 126, 216
    	
 
    
	
Discount 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
-18,200
    	
 
    	
For   site 215 not active
    	
 
    
	
Audits
    	
 
    	
 
    	
 
    	
X
    	
 
    	
9,000
    	
 
    	
Site   125, 126, 216
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Close-Out
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Close-Out Visits
    	
 
    	
 
    	
 
    	
X
    	
 
    	
9,000
    	
 
    	
Site   125, 126, 216
    	
 
    
	
Discount
    	
 
    	
 
    	
 
    	
 
    	
 
    	
-3,000
    	
 
    	
For   site 215 not active
    	
 
    
	
Final Archiving (to be negotiated separately)
    	
 
    	
 
    	
 
    	
 
    	
 
    	
0
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Synarc Research Laboratory
    	
 
    	
 
    	
 
    	
 
    	
 
    	
99,450
    	
 
    	
Extra   lab kits and project management; shipment as pass through
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1.TOTAL (EURO)
    	
 
    	
 
    	
 
    	
 
    	
 
    	
425,906
    	
 
    	
 
    	
 
    

 

4

 

	
Start-up Cost for the new HK site   
    

 

	
Equipment
    	
 
    	
Cost (HKD)
    	
 
    	
Remarks
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Centrifuge
    	
 
    	
75,000.00
    	
 
    	
Eppendoff
    	
 
    	
1   TOTAL
    	
 
    	
€
    	
425,906.15
    	
 
    
	
ECG
    	
 
    	
25,000.00
    	
 
    	
Schiller   AG
    	
 
    	
2   TOTAL
    	
 
    	
€
    	
16,353.00
    	
 
    
	
Refrigerator 4oC
    	
 
    	
8,000.00
    	
 
    	
Non-medical
    	
 
    	
3   TOTAL
    	
 
    	
€
    	
215,016.69
    	
 
    
	
Freezer -18 to -20oC
    	
 
    	
10,000.00
    	
 
    	
Non-medical
    	
 
    	
PASS-THROUGH
    	
 
    	
€
    	
176,680.92
    	
 
    
	
Thermometer (x3)
    	
 
    	
1,050.00
    	
 
    	
HKD350   each
    	
 
    	
TOTAL
    	
 
    	
€
    	
833,956.76
    	
 
    
	
Printer
    	
 
    	
3,000.00
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Internet 10G with emergency phone   number
    	
 
    	
6,000.00
    	
 
    	
USB   HKD400/ month
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Balance
    	
 
    	
2,980.00
    	
 
    	
Charder   MS4900
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Standiometer
    	
 
    	
18,500.00
    	
 
    	
Holtain
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
WelchAllyn Connex ProBP Monitor
    	
 
    	
7,000.00
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
2. TOTAL 
    	
 
    	
163,530
    	
 
    	
€
    	
16,353.00
    	
 
    	
 
    	
 
    	
 
    	
 
    
												

 

	
CT - Service
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
QCT up to 300 scans:
    	
 
    	
$
    	
211,304.00
    	
 
    	
Pass-Through
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
QCT from 300 to 534:
    	
 
    	
$
    	
15,210.00
    	
 
    	
Pass-Through
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CT up to 300 scans:
    	
 
    	
$
    	
0.00
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CT from 300 to 534:
    	
 
    	
$
    	
245,302.20
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Additional DCF’s:
    	
 
    	
$
    	
5,300.00
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
SubTotal (USD)
    	
 
    	
$
    	
250,602.20
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Nordic Management Fee 10% 
    	
 
    	
$
    	
25,060.22
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PASS-THROUGH (QCT)
    	
 
    	
$
    	
226,514.00
    	
 
    	
€
    	
 176,680.92
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Total 
    	
 
    	
$
    	
275,662.42
    	
 
    	
€
    	
 215,016.69
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

(e) The “Payment Schedule” set forth in Attachment B to Work Statement NB-1 (Attachment 2 to the Agreement) is amended to add a new Paragraph (15) immediately following Paragraph (14) of the Payment Schedule, which shall read in full as follows:

 

“(15) The total purchase price for the A6 Services shall be €833,957 assuming 534 CT and QCT scans are completed under this Amendment No. 6 and shall be paid solely in cash denominated in euros, as follows:

 

(a)  €326,456 for the net extra site activities

 

(b) €99,450 for extra lab kits, project management and shipment as a pass through

 

(c) €16,353 for the start-up costs for the additional Hong Kong site.

 

(d) €215,017 for obtaining and analysis of the additional CT scans greater than 300 including the NB management fee.

 

(e) €176,681 for obtaining the additional QCT scans.

 

Radius shall pay NB €376,968 of these incremental fees within 15 days of the effective date representing (i) €261,165 equal to 80 per cent of the net extra site activities; plus (ii)  the total Hong Kong start-up costs of €16,353; plus (iii) €99,450 for the extra lab kits and project management. Radius shall pay NB for the shipments costs as pass-through costs as incurred. Radius shall pay NB the balance for obtaining and analyzing the additional CT-scans and for obtaining the QCT-scans as well as any additional DCF and shipments costs as pass-through costs as incurred. Radius shall pay the balance of costs for the A6 Services of €65,291 when the study database for the clinical study that is the subject of Work Statement NB-1 is locked and transferred to Radius”

 

(g)  The “Trial Activities and Delegation of Responsibilities” table set forth in Attachment C to Work Statement NB-1 (Attachment 2 to the Agreement), as amended, shall apply to New Sites managed by NB.

 

5

 

2.  Ratification.  Except to the extent expressly amended by this Amendment No. 6, all of the terms, provisions and conditions of the Agreement and Work Statement NB-1 are hereby ratified and confirmed and shall remain in full force and effect. The term “Work Statement NB-1”, as used in the Agreement, shall henceforth be deemed to be a reference to Work Statement NB-1 as amended by this Amendment No. 6.

 

3.  General.  This Amendment No. 6 may be executed in counterparts, each of which will be deemed an original with all such counterparts together constituting one instrument

 

[remainder of this page intentionally left blank - signature page follows]

 

6

 

IN WITNESS WHEREOF the parties have caused this Amendment No.6 to be executed by their respective duly authorized officers, and have duly delivered and executed this Amendment No. 6 under seal as of the Amendment Date.

 

 

	
RADIUS HEALTH, INC.
    	
 
    	
NORDIC   BIOSCIENCE CLINICAL DEVELOPMENT VII A/S
    
	
 
    	
 
    	
 
    
	
/s/   Robert E. Ward
    	
 
    	
/s/   Jeppe Ragnar Andersen
    
	
By:   R. E. Ward
    	
 
    	
By:   Jeppe Ragnar Andersen
    
	
Title:   President & CEO
    	
 
    	
Title:   CEO
    
	
 
    	
 
    	
 
    
	
Notice   Address
    	
 
    	
Notice   Address
    
	
Radius   Health, Inc.
    	
 
    	
Nordic   Bioscience Clinical Development VII A/S
    
	
201 Broadway, 6th Floor
    	
 
    	
Herlev   Hovedgade 207
    
	
Cambridge, MA 02139
    	
 
    	
2730 Herlev
    
	
USA
    	
 
    	
Denmark
    
	
Attn:   President
    	
 
    	
Attn:   Clinical Trial Leader &   Medical Advisor / Clinical Studies
    
	
Phone:   01.617.444.1834
    	
 
    	
Phone:   45.4452.5251
    
	
Fax:   01.617.551.4701
    	
 
    	
Fax:   45.4452.525

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]